275 related articles for article (PubMed ID: 23301927)
21. Detrusor Pressures Change with Repeat Filling Cystometry in Myelodysplastic Children with Neurogenic Lower Urinary Tract Dysfunction.
Ergun R; Sekerci CA; Tanidir Y; Atmis B; Gemici A; Yucel S
J Urol; 2021 Feb; 205(2):577-585. PubMed ID: 32897763
[TBL] [Abstract][Full Text] [Related]
22. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
Kuo HC; Liu HT; Chancellor MB
Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
[TBL] [Abstract][Full Text] [Related]
23. Does surgical release of secondary spinal cord tethering improve the prognosis of neurogenic bladder in children with myelomeningocele?
Tarcan T; Onol FF; Ilker Y; Simsek F; Ozek M
J Urol; 2006 Oct; 176(4 Pt 1):1601-6; discussion 1606. PubMed ID: 16952698
[TBL] [Abstract][Full Text] [Related]
24. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women.
Liu HT; Chancellor MB; Kuo HC
BJU Int; 2008 Nov; 102(10):1440-4. PubMed ID: 18489524
[TBL] [Abstract][Full Text] [Related]
25. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom.
Kim JC; Park EY; Hong SH; Seo SI; Park YH; Hwang TK
Int J Urol; 2005 Oct; 12(10):875-80. PubMed ID: 16323980
[TBL] [Abstract][Full Text] [Related]
26. Nerve growth factor does not seem to be a biomarker for neurogenic lower urinary tract dysfunction after spinal cord injury.
Krebs J; Pavlicek D; Stoyanov J; Pannek J; Wöllner J
Neurourol Urodyn; 2017 Mar; 36(3):659-662. PubMed ID: 26950046
[TBL] [Abstract][Full Text] [Related]
27. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity.
Liu HT; Tyagi P; Chancellor MB; Kuo HC
BJU Int; 2010 Dec; 106(11):1681-5. PubMed ID: 19751258
[TBL] [Abstract][Full Text] [Related]
28. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
[TBL] [Abstract][Full Text] [Related]
29. Urinary nerve growth factor in women with overactive bladder syndrome.
Liu HT; Chen CY; Kuo HC
BJU Int; 2011 Mar; 107(5):799-803. PubMed ID: 20804479
[TBL] [Abstract][Full Text] [Related]
30. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
31. Initial urological evaluation and management of children with neurogenic bladder due to myelomeningocele.
Sager C; Burek C; Corbetta JP; Weller S; Ruiz J; Perea R; Lago E; Gomez Y; Durán V; López JC
J Pediatr Urol; 2017 Jun; 13(3):271.e1-271.e5. PubMed ID: 28215830
[TBL] [Abstract][Full Text] [Related]
32. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity.
Giannantoni A; Di Stasi SM; Nardicchi V; Zucchi A; Macchioni L; Bini V; Goracci G; Porena M
J Urol; 2006 Jun; 175(6):2341-4. PubMed ID: 16697870
[TBL] [Abstract][Full Text] [Related]
33. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
34. Long-term urological impact of fetal myelomeningocele closure.
Clayton DB; Tanaka ST; Trusler L; Thomas JC; Pope JC; Adams MC; Brock JW
J Urol; 2011 Oct; 186(4 Suppl):1581-5. PubMed ID: 21862080
[TBL] [Abstract][Full Text] [Related]
35. The management of adolescents with neurogenic urinary tract and bowel dysfunction.
de Kort LM; Bower WF; Swithinbank LV; Marschall-Kehrel D; de Jong TP; Bauer SB
Neurourol Urodyn; 2012 Sep; 31(7):1170-4. PubMed ID: 22460386
[TBL] [Abstract][Full Text] [Related]
36. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident.
Liu HT; Liu AB; Chancellor MB; Kuo HC
BJU Int; 2009 Oct; 104(8):1158-62. PubMed ID: 19338537
[TBL] [Abstract][Full Text] [Related]
37. Urological outcome after myelomeningocele: 20 years of follow-up.
Thorup J; Biering-Sorensen F; Cortes D
BJU Int; 2011 Mar; 107(6):994-9. PubMed ID: 20860652
[TBL] [Abstract][Full Text] [Related]
38. [Urodynamic changes after bladder augmentation surgery in paediatric patients with myelomeningocele due to neurogenic bladder].
Zaragoza Torres RI; Galarza-Flores ME; Gómez-Castellanos JC; Barrera-de León JC
Cir Cir; 2016; 84(2):115-20. PubMed ID: 26707251
[TBL] [Abstract][Full Text] [Related]
39. Microscopic findings in a neurogenic bladder caused by myelomeningocele.
Janzen J; Soni BM
Spinal Cord; 2005 Jan; 43(1):65-6. PubMed ID: 15303113
[No Abstract] [Full Text] [Related]
40. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
Urology; 2017 May; 103():214-217. PubMed ID: 28161379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
